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Background: Although the diagnosis of chondrosarcoma, especially the distinction between enchondroma and
low-grade chondrosarcoma or low-grade chondrosarcoma and high-grade chondrosarcoma, is pathologically
difficult, differential diagnosis is very important because the treatment strategies for these diseases are completely
different. The grading system is crucial in predicting biologic behavior and prognosis, however, exact pathological
grading is difficult using only routine examinations because the criteria of the grading system are not necessarily
definitive. Growth arrest and DNA damage-inducible protein 45b (GADD45b) is an essential molecule for
chondrocytes during terminal differentiation. In the present study, we investigated the immunohistochemical
expression of GADD45b in enchondroma, and chondrosarcoma of histological grades I, II, and III, to clarify the
diagnostic significance of GADD45b in pathological grading of chondrosarcoma.
Methods: Twenty samples (enchondroma = 6, chondrosarcoma grade I = 7, grade II = 6, grade III = 1) were used
for immunohistochemical analysis to investigate the expression of GADD45b. Quantitative analysis was performed
to compare the number of GADD45b positive cells and pathological grading.
Results: Over 70% of the cells in enchondromas expressed GADD45b. On the other hand, the expression of
GADD45b decreased significantly according to the histological grade of chondrosarcoma (grade I: 45%; grade II:
13.8%; and grade III: 3.8%).
Conclusions: The association of GADD45b expression and pathological grading of chondrosarcoma in the present
study suggests that the immunohistochemical study of GADD45b may be a specific diagnostic parameter for
chondrosarcoma cell differentiation.
Background
Chondrosarcoma is the second most frequent primary
malignant bone tumor [1,2]. Because of its recalcitrance
to chemotherapy and radiotherapy, chondrosarcoma is
primarily treated with surgery, and the clinical prognosis
of chondrosarcoma has been correlated with the grading
of the histological malignancy [3].
For pathological consideration, distinguishing benign
(enchondroma) from low-grade chondrosarcoma, or low-
grade chondrosarcoma from high-grade chondrosarcoma,
is one of the most frequent diagnostic dilemmas facing
orthopedic oncologists.
Enchondroma is a very common and benign cartilagi-
nous tissue tumor that occurs within bones. Approxi-
mately 69% of the patients are in the first and second
decades of life [4]. More than 49% of the tumors are in the
small bones of the hands and feet, particularly in the pha-
langes. Unlike chondrosarcoma, enchondroma rarely
develops in the pelvis or ribs. The pathological distinction
between enchondroma and low-grade chondrosarcoma is,
however, not always easy because of their similar cytology
and cellularity. Chondrosarcoma has a broad array of pre-
sentations in pathology and clinical course. Chondrosar-
coma is primarily a tumor of adulthood and old age.
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sixth decades. More than two-thirds of the tumors are in
the trunk, including the pelvis, ribs, and shoulder girdle.
The pathological grading of chondrosarcoma is based on
cellularity, nuclear atypia, and pleomorphism [5]; however,
in some borderline cases, exact histological grading is diffi-
cult using only routine histopathological examinations
because the criteria of the grading system are not necessa-
rily definitive [6]. Therefore, correlative interpretation of
histopathological, imaging, and clinical information is cur-
rently used for making this distinction.
Several authors have reported supplementary methods,
including the evaluation of DNA synthesis and content
[7,8], flow cytometry [9], p53 [10], MIB-1 [11], COX-2
[6], and p21 [3], to assess the prognosis of patients with
chondrosarcoma. These methods are, however, based on
non-specific phenomena in chondrocytic differentiation.
Chondrogenesis, i.e., cartilage formation including
chondrocyte differentiation and maturation, is a process
that occurs during skeletal development. This process
occurs in stages beginning with mesenchymal cell
recruitment and migration, proliferation, and condensa-
tion, followed by chondroprogenitor cell determination
and differentiation. Finally, chondrocyte differentiation
is terminated by hypertrophy. Bone morphogenetic pro-
teins (BMPs), which were originally identified as mole-
cules that induce ectopic endochondral ossification [12],
set the stage for bone morphogenesis by initiating chon-
droprogenitor cell determination and differentiation and
regulate the later stages of chondrocyte maturation and
hypertrophic phenotype [13].
We previously reported the growth arrest and DNA
damage-inducible protein 45b (GADD45b) as an early
responding gene to BMP-2 stimulation in the chondro-
cyte cell line [14]. The expression of GADD45b gradu-
ally increased along with chondrocyte differentiation
from the proliferation phase to hypertrophic phase.
GADD45b stimulates MMP-13 (a marker of terminal
differentiation of hypertrophic chondrocytes) promoter
activity in chondrocytes through the JNK-mediated
phosphorylation of JunD, partnered with Fra2 and in
synergy with Runx2. These facts suggested that
GADD45b plays an essential role during chondrocyte
terminal differentiation.
In the present study, we investigated the immunohis-
tochemical expression of GADD45b in enchondroma
and chondrosarcoma of histological grades I, II, and III,
to clarify the diagnostic significance of GADD45b in his-
tological grading of chondrosarcoma.
Methods
Study samples
Formalin-fixed, paraffin-embedded tissues collected
between 1978 and 2009 were obtained from the
Department of Pathology, Graduate School of Medical
and Dental Sciences, Kagoshima University upon
approval of the ethics committee. The characteristics of
the patients are summarized in Table 1.
Pathological review and grading
Histological slides of the tumors from all the patients
were reviewed by 2 or 3 pathologists. The histological
diagnosis was based on the textbook definition [15]. The
histological grade of the chondrosarcomas was deter-
mined on the basis of the nuclear size, nuclear staining
(hyperchromasia), and cellularity according to the
World Health Organization Classification of Bone
Tumors (2002) [15].
Immunohistochemical analysis
The immunohistochemical analysis was performed using
the labeled streptavidin-biotin method using goat poly-
clonal anti-human GADD45b (C-18; 1:1000) antibody
( S a n t aC r u zB i o t e c h n o l o g y ,I n c .C A ,U S A ) .T h er e s u l t s
were evaluated by 2 investigators, who were unaware of
the pathological grading of the samples. We calculated
the proportion of stained tumor cells after performing
nuclear staining.
Quantitative analysis of the GADD45b immunoreac-
tive cells was performed. The immunostained sections
were photographed at 100× magnification with a micro-
scope, and the GADD45b immunoreactive cells and
non-positive cells were counted in 4 fields. We







1 ♂/43 Femur Enchondroma 68.9
2 ♂/16 Metatarsal Enchondroma 81.6
3 ♀/46 Phalanx Enchondroma 74.4
4 ♂/32 Phalanx Enchondroma 83.5
5 ♀/58 Femur Enchondroma 66.6
6 ♀/54 Phalanx Enchondroma 68.8
7 ♀/52 Femur CSA grade I 67.3
8 ♂/39 Pelvis CSA grade I 55.5
9 ♀/46 Femur CSA grade I 44.6
10 ♂/61 Femur CSA grade I 49.2
11 ♂/18 Tibia CSA grade I 29.8
12 ♂/67 Mandible CSA grade I 38.1
13 ♀/32 Pelvis CSA grade I 31.0
14 ♀/50 Femur CSA grade II 11.8
15 ♀/64 Rib CSA grade II 3.9
16 ♀/72 Femur CSA grade II 14.8
17 ♀/55 Pelvis CSA grade II 5.9
18 ♂/44 Femur CSA grade II 11.9
19 ♂/67 Mandible CSA grade II 34.0
20 ♂/61 Mandible CSA grade III 3.8
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Statistical comparisons in each grade (enchondroma,
grade I and II) were performed by a one-way ANOVA
using Stat-View version 5.0. If significance was achieved,
a post-hoc Fisher’s protected least significant differences
(PLSD) test was performed to determine whether signifi-
cant differences existed. Significance was set at p < 0.05.
Results
The patient data and lesion characteristics are listed in
Table 1. There were 6 cases of enchondroma and 14 of
chondrosarcoma, including 7 with grade I, 6 with grade
II, and 1 with grade III. Enchondromas, on average,
showed 74% reactivity for GADD45b (68.9-83.5%). In
the case of chondrosarcomas, the percentage of
GADD45b positive cells was inversely proportional to
the tumor grade. GADD45b was expressed in 45%
(29.8-67.3%) of the cells in grade I chondrosarcoma and
13.8% (1.2-34.1%) of cells in grade II. There were statis-
tically significant differences among the three groups
except grade III chondrosarcoma. (Fig. 1)
In grade II chondrosarcomas, comparatively mature
cells, which had plump nuclei and were surrounded by
cartilage matrix, were positive for GADD45b.I nc o n -
trast, most of the atypical spindle cells, which had
enlarged hyperchromatic nuclei and myxomatous
matrix, were negative. (Fig. 2C) Although we had only 1
case of grade III chondrosarcoma, only 3.8% of the cells
were positive for GADD45b.
Discussion
The pathological grade of chondrosarcomas is considered
to be the most useful predictor of the clinical outcome
and course of the treatment for these tumors. While cri-
teria for pathological grade of chondrosarcomas have
been published, the application of these criteria is diffi-
cult and requires expert judgement [16].
Figure 1 Percentages of GADD45b positive cells.
Figure 2 Immunohistochemical staining for GADD45b A) Enchondroma, B) Grade I Chondrosarcoma, C) Grade II Chondrosarcoma, D)
Grade III Chondrosarcoma. Chondrocytes which have plump nuclei and are surrounded by cartilage matrix, are positive for GADD45b.I n
contrast, most of the atypical and immature cells in grade II or III chondrosarcoma are negative. Over 70% of the cells in enchondromas
expressed GADD45b. In chondrosarcomas, the rate of GADD45b positive cells was inversely proportional to its grade. There were statistically
significant differences among three groups except grade III chondrosarcoma. (*: P < 0.01).
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cal, imaging, and clinical information is currently used
as a method to provide the appropriate prognostic infor-
mation. Recently, the reliability of histopathological and
radiological grading of cartilaginous neoplasms in long
bones was studied by 9 recognized musculoskeletal
pathologists and 8 recognized musculoskeletal radiolo-
gists [17]. They reviewed 49 consecutive cases of cartila-
ginous lesions in long bones and estimated the
interobserver reliability for the grading of cartilaginous
neoplasms in long bones to be 0.443 for pathologists
and 0.345 for radiologists. These data demonstrate that
the interpretation of histopathological features from car-
tilaginous lesions has some limits. These data encour-
aged the efforts to develop better prospective
pathological interpretation algorithms or better prospec-
tive imaging protocols.
The present study provides the first immunohisto-
chemical evidence that GADD45b expression is signifi-
cantly associated with the grading of chondrosarcomas.
GADD45b is a member of the GADD45 family of small
(18 kDa) proteins, which are known to be associated
with cell growth control, apoptotic cell death, and the
cellular response to DNA damage [18]. Initially,
GADD45b encoded by MyD118 was identified as a mye-
loid differentiation primary response gene activated by
IL-6 in murine myeloid leukemia cells upon induction
of terminal differentiation [19].
Formation of the vertebral skeleton through endochon-
dral ossification is a physiological process, which involves
progressive differentiation of proliferating chondrocytes
to growth-arrested hypertrophic chondrocytes. Interest-
ingly, the GADD45b protein localized prominently in the
nucleus of the late-stage hypertrophic chondrocytes, but
not of the proliferating chondrocytes. Although
GADD45b is an abundant protein in chondrocytes, over-
expression of GADD45b in terminally differentiated
chondrocytes in the growth plate promotes JNK and p38
signaling cascades to regulate both MMP-13 and
Col10a1 expression, which are crucial for the mainte-
nance of the terminal differentiated phenotype [20].
Therefore, the association of GADD45b expression and
pathological grading of chondrosarcoma in the present
study suggests that immunohistochemical study of
GADD45b may be a specific diagnostic parameter for
chondrosarcoma cell differentiation.
In this study, there was overlap in the proportion of
GADD45b-expressing cells between enchondroma and
grade I chondrosarcoma (CSA), as shown for Case 7,
and between grade I CSA and grade II CSA, as shown
for Case 19. The limitation of this pilot study of
GADD45b expression in chondrogenic tumors was the
small number of subjects. Therefore, the study should
be conducted on a larger number of subjects to
determine whether the number of such “overlap” cases
would increase.
Conclusions
In conclusion, our data suggests that immunohisto-
chemical study of GADD45b provides valuable diagnos-
tic information and facilitates examination of
histological grading. More studies involving larger num-
ber of patients must be performed to further character-
ize its potential diagnostic validity.
Acknowledgements
This research was supported by KAKENHI-20591787(KI).
Author details
1Orthopaedic Surgery, Graduate School of Medical and Dental Sciences,
Kagoshima University, Kagoshima, Japan.
2Molecular and Cellular Pathology,
Graduate School of Medical and Dental Sciences, Kagoshima University,
Kagoshima, Japan.
3School of Health Sciences, Faculty of Medicine,
Kagoshima University, Kagoshima, Japan.
Authors’ contributions
ZM, AT, MY, SN carried out the immunohistochemical studies. TY, YI
participated in the design of the study, and SH contributed in the statistical
analysis. SK and KI conceived the study and drafted the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 August 2010 Accepted: 13 October 2010
Published: 13 October 2010
References
1. Larsson SE, Lorentzon R: The incidence of malignant primary bone
tumours in relation to age, sex and site. A study of osteogenic sarcoma,
chondrosarcoma, and Ewing’s sarcoma diagnosed in Sweden from 1958
to 1968. J Bone joint Surg Br 1974, 56:534-540.
2. Hartley AL, Blair V, Harris M, Birch JM, Banerjee SS, Freemont AJ, McClure J,
McWilliam LJ: Sarcomas in north west England:II. Incidence. Br J Cancer
1991, 64:1145-1150.
3. Hiraoka K, Zenmyo M, Komiya S, Kawabata R, Yokouchi M, Suzuki R,
Hamada T, Kato S, Nagata K: Relationship of p21(waf1/cip1) and
differentiation on chondrosarcoma cells. Virchows Arch 2002, 440:285-290.
4. Unni KK: General aspects and data on 11,087 cases. In Dahlin’s bone
tumor Edited by: Lippincott-Raven, Minnesota , Fifth 1996, 25.
5. Bertoni HD, Czerniak B: Malignant cartilage tumor. Bone tumors (Mo):
Mosby, St Louis 1998, 353-440.
6. Endo M, Matsumura T, Yamaguchi T: Cyclooxygenase-2 overexpression
associated with a poor prognosis in chondrosarcomas. Human pathology
2006, 37:471-476.
7. Alho A, Skjeldal S, Melvik JE, Pettersen EO, Larsen TE: The clinical
importance of DNA synthesis and aneuploidy in bone and soft tissue
tumours. Anticancer Res 1993, 13:2383-2387.
8. Kreicbergs A, Boquist L, Borssén B, Larsson SE: Prognostic factors in
chondrosarcoma: a comparative study of cellular DNA content and
clinicopathologic features. Cancer 1982, 50:577-583.
9. Alho A, Connor JF, Mankin HJ, Schiller AL, Campbell CJ: Assessment of
malignancy of cartilage tumors using flow cytometry. A preliminary
report. J Bone Joint Surg Am 1983, 65:779-785.
10. Dobashi Y, Sugimura H, Sato A, Hirabayashi T, Kanda H, Kitagawa T,
Kawaguchi N, Imamura T, Machinami R: Possible association of p53
overexpression and mutation with high-grade chondrosarcoma. Diagn
Mol Pathol 1993, 2:257-263.
11. Nawa G, Ueda T, Mori S, Yoshikawa H, Fukuda H, Ishiguro S, Funai H,
Uchida A: Prognostic significance of Ki67(MIB-1) proliferation index and
p53 over-expression in chondrosarcomas. Int J Cancer 1996, 69:86-9.
Zenmyo et al. Diagnostic Pathology 2010, 5:69
http://www.diagnosticpathology.org/content/5/1/69
Page 4 of 512. Urist MR: Bone: Formation by autoinduction. Science 1965, 150:893-899.
13. Goldring MB, Tsuchimochi K, Ijiri K: The control of chondrogenesis. J
Cellular Biochem 2006, 97:33-44.
14. Ijiri K, Zerbini LF, Peng H, Correa RG, Lu B, Walsh N, Zhao Y, Taniguchi N,
Huang XL, Otu H, Wang H, Wang JF, Komiya S, Ducy P, Rahman MU,
Flavell RA, Gravallese EM, Oettgen P, Libermann TA, Goldring MB: A novel
role for Gadd45b as a mediator of MMp-13 gene expression during
chondrocyte terminal differentiation. J Biol Chem 2005, 280:38544-38554.
15. Bertoni F, Bacchini P, Hogendoorn PCW: Chondrosarcoma. In World health
Organization Classification of Tumours. Pathology and genetics of tumours of
soft tissue and bone. Edited by: Fletcher CDM, Unni KK, Mertens F. IARC
Press, Lyon; 2002:247-251.
16. Murphey MD, Flemming DJ, Boyea SR, Bojescul JA, Sweet DE, Temple HT:
Enchondroma versus chondrosarcoma in the appendicular skeleton:
differentiating features. Radiographics 1998, 18:1213-1237.
17. Skeletal lesions interobserver correlation among expert diagnosticians study
group: Reliability of histopathological and radiologic grading of
cartilaginous neoplasms in long bones. J Bone joint Surg Am 2007,
89:2113-2123.
18. Amanullah A, Azam N, Balliet A, Hollander C, Hoffman B, Fornace A,
Liebermann D: Cell signalling: cell survival and a Gadd45-factor
deficiency. Nature 2003, 424:741-742.
19. Selvakumaran M, Lin HK, Sjin RT, Reed JC, Liebermann DA, Hoffman B: The
novel primary response gene MyD118 and the proto-oncogenes myb,
myc, and bcl-2 modulate transforming growth factor beta 1-induced
apoptosis of myeloid leukemia cells. Mol Cell Biol 1994, 14:2352-2360.
20. Tsuchimochi K, Otero M, Dragomir CL, Plumb DA, Zerbini LF, Libermann TA,
Marcu KB, Komiya S, Ijiri K, Goldring MB: Gadd45beta enhances Col10a1
transcription via the MTK1/MKK3/6/p38 axis and activation of C/
EBPbeta-TAD4 in terminally differentiating chondrocytes. J Biol Chem
2010, 285:8395-83407.
doi:10.1186/1746-1596-5-69
Cite this article as: Zenmyo et al.: Gadd45b expression in
chondrosarcoma: A pilot study for diagnostic and biological
implications in histological grading. Diagnostic Pathology 2010 5:69.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zenmyo et al. Diagnostic Pathology 2010, 5:69
http://www.diagnosticpathology.org/content/5/1/69
Page 5 of 5